Syndax Pharmaceuticals (Nasdaq: SNDX) reported that on August 1, 2026, it granted stock option inducement awards covering up to 59,250 shares of common stock to five new employees under its 2023 Inducement Plan. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
These are options rather than an immediate share issuance: if exercised, up to 59,250 additional common shares could reduce existing holders’ percentage ownership under the dilution mechanism, while vesting delays the awards—25% after one year and the balance monthly over 36 months, subject to continued service.
Market Context
The prior inducement-grant announcement, news_id 1077238, was followed by a 4.45% 24-hour gain, whil...
Analysis
The prior inducement-grant announcement, news_id 1077238, was followed by a 4.45% 24-hour gain, while current insider activity was Net Selling. That record adds share-issuance and ownership context to this employee-award disclosure.
Key Figures
Inducement shares:59,250 sharesRecipients:five new employeesGrant date:August 1, 2026+4 more
7 metrics
Inducement shares59,250 sharesGranted to five new employees
Recipientsfive new employeesAugust 1, 2026 inducement awards
Grant dateAugust 1, 2026Inducement awards
Vesting periodfour yearsStock options
Initial vesting25%Underlying shares vest on the one-year anniversary
Monthly vesting1/48thMonthly thereafter over 36 months
Remaining vesting period36 monthsMonthly vesting after the one-year anniversary
"the Company granted inducement awards to purchase up to 59,250 shares"
Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.
menin inhibitormedical
"Revuforj® (revumenib), an FDA-approved menin inhibitor"
A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.
monoclonal antibodymedical
"Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
CSF-1 receptormedical
"antibody that blocks the colony stimulating factor 1 (CSF-1) receptor"
A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan.The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
FAQ
What inducement stock option grants did Syndax Pharmaceuticals (SNDX) announce on August 5, 2026?
Syndax Pharmaceuticals announced inducement stock option grants for up to 59,250 shares of common stock to five new employees. According to Syndax, these options were issued under its 2023 Inducement Plan and are intended as employment inducement awards.
How do the new SNDX inducement stock options vest for Syndax employees?
The inducement stock options vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date. According to Syndax, the remaining 75% vests in equal 1/48th monthly installments over the next 36 months, subject to continued service.
How many employees received inducement awards in Syndax Pharmaceuticals’ August 2026 grant?
Five new employees received inducement stock option awards in the August 1, 2026 grant. According to Syndax, these awards collectively cover up to 59,250 shares of common stock and were issued under the company’s 2023 Inducement Plan as part of employment offers.
Under which equity plan were the August 2026 SNDX inducement options granted?
The August 2026 inducement options were granted under Syndax’s 2023 Inducement Plan. According to Syndax, this plan is used specifically for employment inducement awards and is separate from its broader equity incentive programs for existing employees and executives.
What does Syndax Pharmaceuticals’ pipeline include alongside these SNDX inducement grants?
Syndax’s pipeline includes Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody targeting CSF-1 receptor. According to Syndax, the company is also conducting several clinical trials across the cancer treatment continuum.
